Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...

MSD's plan to reduce its headcount by around 6,000, first revealed a couple of weeks ago, looks like it will start at its headquarters in Rahway, New Jersey. Confirmation of that has come in the form ...

MSD is a company that is ‘serious about science.’ In 2024, its global research and development investment reached $17.9 ...

MSD in the Philippines’ “Di Mo DeCERV!” campaign has been awarded Bronze in the Advocacy category at this year’s ICE Awards, ...

Merck & Co (MSD) has taken the first of two possible plunges in its ongoing collaboration with Evaxion, gaining the rights to a mystery infectious disease vaccine candidate. The US big pharma decided ...

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...